Shiwen Peng

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
    Shiwen Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Biomed Sci 18:21. 2011
  2. pmc RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency
    Bruce Huang
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Hum Gene Ther 19:763-73. 2008
  3. ncbi Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies
    Shiwen Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Biomed Sci 12:689-700. 2005
  4. pmc Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery
    Simon R Best
    Department of Otolaryngology Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Vaccine 27:5450-9. 2009
  5. pmc Characterization of human papillomavirus type 11-specific immune responses in a preclinical model
    Shiwen Peng
    Department of Otolaryngology Head and Neck Surgery, Baltimore, Maryland 21287, USA
    Laryngoscope 120:504-10. 2010
  6. pmc Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency
    Bruce Huang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Vaccine 25:7824-31. 2007
  7. pmc Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine
    Shiwen Peng
    Department of Otolaryngology Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    Cancer Immunol Immunother 62:171-82. 2013
  8. pmc Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3
    Cornelia L Trimble
    Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Cancer Immunol Immunother 59:799-803. 2010
  9. pmc Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion
    Ken Yu Lin
    Department of Pathology, Institute of Genetic Medicine, Johns Hopkins Medical Institutions, 1550 Orleans Street, Baltimore, MD 21231, USA
    Cancer Res 67:1832-41. 2007
  10. pmc In vivo microRNA-155 expression influences antigen-specific T cell-mediated immune responses generated by DNA vaccination
    Chih Ping Mao
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Cell Biosci 1:3. 2011

Collaborators

Detail Information

Publications24

  1. pmc Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
    Shiwen Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Biomed Sci 18:21. 2011
    ..In addition, we determined that inducible nitric oxide synthase (iNOS) plays a role in the immune suppression caused by DMXAA administration before DNA vaccination. Our study has significant implications for future clinical translation...
  2. pmc RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency
    Bruce Huang
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Hum Gene Ther 19:763-73. 2008
    ..Thus, intradermal administration of DNA encoding shRNA represents a plausible approach to silence genes in vivo and a potentially useful tool to enhance DNA vaccine potency...
  3. ncbi Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies
    Shiwen Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Biomed Sci 12:689-700. 2005
    ..Our data indicate that all of the intracellular targeting and intercellular spreading strategies that have been shown to enhance E7 DNA vaccine potency were also able to enhance E6 DNA vaccine potency...
  4. pmc Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery
    Simon R Best
    Department of Otolaryngology Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Vaccine 27:5450-9. 2009
    ..We conclude that electroporation is a promising method for delivery of HPV DNA vaccines and should be considered for DNA vaccine delivery in human clinical trials...
  5. pmc Characterization of human papillomavirus type 11-specific immune responses in a preclinical model
    Shiwen Peng
    Department of Otolaryngology Head and Neck Surgery, Baltimore, Maryland 21287, USA
    Laryngoscope 120:504-10. 2010
    ..Therefore, we developed a novel, therapeutic DNA vaccine targeting HPV-11 and characterized the in vivo immunologic responses generated against HPV-11 E6 and E7 after DNA vaccination in a preclinical model...
  6. pmc Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency
    Bruce Huang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Vaccine 25:7824-31. 2007
    ..Furthermore, we show that mice treated with SCT-E6 and Bcl-xL DNA generated enhanced anti-tumor effects against E6-expressing tumor cells (TC-1/Luciferase) compared to mice treated with SCT-E6 and mtBcl-xL DNA...
  7. pmc Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine
    Shiwen Peng
    Department of Otolaryngology Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    Cancer Immunol Immunother 62:171-82. 2013
    ..We recommend a single, preconditioning dose of CTX prior to vaccination due to its efficacy, ease of administration, and reduced cumulative adverse effect on vaccine-induced T cells...
  8. pmc Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3
    Cornelia L Trimble
    Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Cancer Immunol Immunother 59:799-803. 2010
    ..This finding suggests that, in the setting of natural infection, immune responses which are involved in elimination of cervical dysplastic epithelium are not represented to any great extent in the systemic circulation...
  9. pmc Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion
    Ken Yu Lin
    Department of Pathology, Institute of Genetic Medicine, Johns Hopkins Medical Institutions, 1550 Orleans Street, Baltimore, MD 21231, USA
    Cancer Res 67:1832-41. 2007
    ..These data provide evidence that tumor expression of VCAM-1 represents a new mechanism of immune evasion and has important implications for the development of immunotherapy for human RCC...
  10. pmc In vivo microRNA-155 expression influences antigen-specific T cell-mediated immune responses generated by DNA vaccination
    Chih Ping Mao
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Cell Biosci 1:3. 2011
    ..abstract:..
  11. pmc Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life
    Shiwen Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Hum Gene Ther 16:584-93. 2005
    ..Our data indicate that transfection of dendritic cells with BAK/BAX siRNA represents a plausible strategy for enhancing dendritic cell-based vaccine potency...
  12. pmc A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3
    Cornelia L Trimble
    Department of Gynecology and Obstetrics, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Clin Cancer Res 15:361-7. 2009
    ..To evaluate the safety and immunogenicity of a therapeutic human papillomavirus (HPV)16 DNA vaccine administered to women with HPV16+cervical intraepithelial neoplasia (CIN)2/3...
  13. pmc Papillomavirus infection requires gamma secretase
    Balasubramanyam Karanam
    Department of Pathology, Johns Hopkins University, Room 308, Cancer Research Building 2, 1550 Orleans St, Baltimore, MD 21231, USA
    J Virol 84:10661-70. 2010
    ....
  14. doi Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies
    Joshua W Wang
    Department of Pathology, The Johns Hopkins University, Baltimore, MD 21231, USA
    Virology 449:304-16. 2014
    ..The PsV and fcPsV-based assays exhibit similar sensitivity for type-specific antibodies elicited by L1 virus-like particles (VLP), but the latter improves detection of L1-specific cross-type neutralizing antibodies. ..
  15. pmc Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity
    Balasubramanyam Karanam
    Department of Pathology, The Johns Hopkins University, Baltimore, MD 21231, USA
    Vaccine 27:1040-9. 2009
    ....
  16. pmc HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions
    Shiwen Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Clin Cancer Res 13:2479-87. 2007
    ..The identification and characterization of endogenously processed HPV antigenic epitopes in closely characterized patient cohorts will provide insight into the reasons for success or failure of therapeutic approaches...
  17. pmc Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma
    Sofia Lyford-Pike
    Department of Otolaryngology Head and Neck Surgery, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    Cancer Res 73:1733-41. 2013
    ....
  18. pmc Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells
    Ravi K Anchoori
    Department of Pathology, Johns Hopkins University, Baltimore, Maryland, United States of America
    PLoS ONE 6:e23888. 2011
    ..Importantly, RAMB1 synergistically triggers cell death of cervical cancer cells when combined with the lysosome inhibitor Chloroquine...
  19. pmc A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer
    Ravi K Anchoori
    Department of Oncology, The Johns Hopkins University, Baltimore, MD 21231, USA
    Cancer Cell 24:791-805. 2013
    ....
  20. pmc Strategy for eliciting antigen-specific CD8+ T cell-mediated immune response against a cryptic CTL epitope of merkel cell polyomavirus large T antigen
    Bianca P Gomez
    Departments of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Cell Biosci 2:36. 2012
    ..abstract:..
  21. ncbi Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities
    Tong Li
    Department of Pathology, The Johns Hopkins University, School of Medicine, Baltimore, Maryland 21205, USA
    J Neurosci 27:10849-59. 2007
    ..Our findings suggest that moderate inhibition of gamma-secretase represents an attractive anti-amyloid therapy for Alzheimer's disease...
  22. pmc Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype
    Cornelia L Trimble
    Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Clin Cancer Res 11:4717-23. 2005
    ..We carried out a prospective observational cohort study evaluating known, quantifiable prognostic variables of clinical behavior in women with high-grade cervical lesions...
  23. pmc DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity
    Shiwen Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Cell Biosci 1:26. 2011
    ..abstract:..
  24. pmc Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6
    Shiwen Peng
    Department of Pathology, Johns Hopkins University School of Medicine, Ross 512H, 720 Rutland Ave, Baltimore, MD 21205, USA
    J Virol 78:8468-76. 2004
    ..Thus, our data indicate that E6 aa48-57 contains the immunodominant epitope and that a CRT/E6 DNA vaccine may be useful for control of HPV infection and HPV-associated lesions...